Latest Period
Q1 2026
Security Snapshot
Editas Medicine, Inc. - Common Stock (EDIT) Institutional Ownership
CUSIP: 28106W103
13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026
Institutions Reporting
203
Shares (Excl. Options)
51,833,232
Price
$2.47
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- EDIT on Nasdaq
- Shares outstanding
- 82,773,190
- Price per share
- $2.89
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 51,833,232
- Total reported value
- $127,497,030
- % of total 13F portfolios
- 0%
- Share change
- +2,096,400
- Value change
- +$5,933,007
- Number of holders
- 203
- Price from insider filings
- $2.89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- EDIT - Editas Medicine, Inc. - Common Stock is tracked under CUSIP 28106W103.
- 203 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 192 to 203 between Q4 2025 and Q1 2026.
- Reported value moved from $102,489,972 to $127,497,030.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 203 institutions filings for Q1 2026.
Security key
28106W103
Latest holder period
Q1 2026
13F holders
203
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
EDIT full holder history
Editas Medicine, Inc. SEC filings
Editas Medicine, Inc. company facts
Editas Medicine, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28106W103:
Significant Owners of Editas Medicine, Inc. - Common Stock (EDIT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.9% | $10,527,922 | 6,539,082 | BlackRock, Inc. | 31 Mar 2025 |
As of 31 Mar 2026, 203 institutional investors reported holding 51,833,232 shares of Editas Medicine, Inc. - Common Stock (EDIT). This represents 63% of the company’s total 82,773,190 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Editas Medicine, Inc. - Common Stock (EDIT) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 9,263,312 | -0.9% | 0% | $22,880,381 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | 4,204,369 | 0% | 0% | $10,384,791 |
| RENAISSANCE TECHNOLOGIES LLC | 4.8% | 3,972,160 | +31% | 0.02% | $9,811,235 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8% | 3,148,570 | 0% | 0% | $7,776,968 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8% | 2,311,789 | +1.2% | 0% | $5,711,437 |
| STATE STREET CORP | 2.5% | 2,076,122 | +5.1% | 0% | $5,128,021 |
| Nuveen, LLC | 2.4% | 1,977,509 | +0.03% | 0% | $4,884,447 |
| JPMORGAN CHASE & CO | 2.4% | 1,947,384 | +149% | 0% | $4,342,666 |
| D. E. Shaw & Co., Inc. | 2.3% | 1,943,893 | +75% | 0% | $4,801,415 |
| Opaleye Management Inc. | 2.3% | 1,926,997 | 0.66% | $4,759,683 | |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 1,549,063 | -5.1% | 0% | $3,826,186 |
| ACADIAN ASSET MANAGEMENT LLC | 1.8% | 1,457,715 | +82% | 0.01% | $3,596,000 |
| AQR CAPITAL MANAGEMENT LLC | 1.7% | 1,370,497 | +113% | 0% | $3,385,127 |
| RAYMOND JAMES FINANCIAL INC | 1.6% | 1,293,848 | +9.2% | 0% | $3,195,805 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.3% | 1,052,457 | +87% | 0.06% | $2,599,569 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1% | 861,326 | +8.4% | 0% | $2,127,475 |
| NORTHERN TRUST CORP | 0.9% | 742,443 | +12% | 0% | $1,833,834 |
| MACKENZIE FINANCIAL CORP | 0.88% | 730,054 | 0% | $1,803,233 | |
| CITADEL ADVISORS LLC | 0.8% | 662,389 | -19% | 0% | $1,636,101 |
| VANGUARD FIDUCIARY TRUST CO | 0.74% | 614,036 | 0% | 0% | $1,516,669 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.7% | 582,309 | -30% | 0.01% | $1,438,303 |
| GOLDMAN SACHS GROUP INC | 0.67% | 558,577 | -37% | 0% | $1,379,685 |
| GSA CAPITAL PARTNERS LLP | 0.52% | 434,413 | -24% | 0.07% | $1,073,000 |
| MORGAN STANLEY | 0.5% | 411,192 | -39% | 0% | $1,015,644 |
| UBS Group AG | 0.48% | 393,754 | -51% | 0% | $972,572 |
Institutional Holders of Editas Medicine, Inc. - Common Stock (EDIT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 51,833,232 | $127,497,030 | +$5,933,007 | $2.47 | 203 |
| 2025 Q4 | 49,948,580 | $102,489,972 | +$13,818,867 | $2.05 | 192 |
| 2025 Q3 | 43,042,863 | $149,310,576 | +$7,918,428 | $3.47 | 191 |
| 2025 Q2 | 41,335,195 | $90,959,890 | -$2,651,384 | $2.20 | 190 |
| 2025 Q1 | 44,017,732 | $51,056,496 | -$8,643,822 | $1.16 | 189 |
| 2024 Q4 | 51,050,083 | $64,829,211 | -$26,980,305 | $1.27 | 199 |
| 2024 Q3 | 55,026,910 | $187,727,875 | -$7,609,494 | $3.41 | 223 |
| 2024 Q2 | 56,388,612 | $263,332,828 | -$55,730,958 | $4.67 | 229 |
| 2024 Q1 | 67,934,083 | $503,995,838 | +$62,859,602 | $7.42 | 221 |
| 2023 Q4 | 58,810,431 | $595,736,469 | -$24,830,057 | $10.13 | 222 |
| 2023 Q3 | 61,671,930 | $481,001,719 | -$15,318,112 | $7.80 | 220 |
| 2023 Q2 | 62,806,728 | $516,820,804 | +$83,105,555 | $8.23 | 234 |
| 2023 Q1 | 52,966,709 | $383,993,662 | -$13,671,500 | $7.25 | 231 |
| 2022 Q4 | 54,069,648 | $479,580,650 | +$43,275,611 | $8.87 | 245 |
| 2022 Q3 | 48,268,099 | $590,813,665 | +$8,782,042 | $12.24 | 243 |
| 2022 Q2 | 47,470,750 | $561,353,937 | +$5,825,446 | $11.83 | 235 |
| 2022 Q1 | 45,377,308 | $862,213,005 | -$137,494,973 | $19.02 | 239 |
| 2021 Q4 | 50,935,353 | $1,354,989,098 | -$58,058,784 | $26.55 | 288 |
| 2021 Q3 | 51,686,909 | $2,124,275,170 | -$9,901,736 | $41.08 | 307 |
| 2021 Q2 | 52,115,846 | $2,960,972,143 | -$42,349,447 | $56.64 | 309 |
| 2021 Q1 | 53,112,966 | $2,230,651,006 | -$37,048,235 | $42.00 | 296 |
| 2020 Q4 | 52,925,101 | $3,710,809,621 | -$146,422,850 | $70.11 | 303 |
| 2020 Q3 | 55,153,663 | $1,547,459,830 | +$15,957,942 | $28.06 | 233 |
| 2020 Q2 | 54,180,331 | $1,601,145,803 | +$263,790,568 | $29.58 | 225 |
| 2020 Q1 | 45,615,983 | $904,572,484 | -$9,115,772 | $19.83 | 186 |
| 2019 Q4 | 45,765,436 | $1,355,110,145 | +$25,771,039 | $29.61 | 221 |
| 2019 Q3 | 44,998,047 | $1,024,181,318 | +$117,742,869 | $22.74 | 180 |
| 2019 Q2 | 39,755,008 | $983,423,600 | +$65,857,366 | $24.74 | 187 |
| 2019 Q1 | 37,451,919 | $915,659,367 | +$73,756,065 | $24.45 | 194 |
| 2018 Q4 | 34,476,789 | $784,057,800 | +$24,196,841 | $22.75 | 187 |
| 2018 Q3 | 33,225,759 | $1,057,110,921 | +$32,891,792 | $31.82 | 192 |
| 2018 Q2 | 32,137,091 | $1,150,684,888 | +$38,224,646 | $35.83 | 208 |
| 2018 Q1 | 31,152,906 | $1,032,691,989 | +$25,997,611 | $33.15 | 192 |
| 2017 Q4 | 30,385,119 | $934,032,943 | +$80,818,257 | $30.73 | 146 |
| 2017 Q3 | 27,385,418 | $657,479,359 | +$43,906,788 | $24.01 | 115 |
| 2017 Q2 | 25,837,623 | $433,614,752 | +$21,311,417 | $16.78 | 107 |
| 2017 Q1 | 27,537,538 | $614,414,843 | +$120,573,551 | $22.32 | 99 |
| 2016 Q4 | 23,494,260 | $381,310,290 | +$21,340,854 | $16.23 | 84 |
| 2016 Q3 | 22,215,862 | $299,468,288 | +$9,006,129 | $13.48 | 71 |
| 2016 Q2 | 17,634,311 | $429,193,163 | -$15,061,641 | $24.40 | 64 |
| 2016 Q1 | 18,151,358 | $625,254,000 | +$464,066,000 | $34.54 | 48 |